Progression-Free Survival (PFS) and Tumor Growth with Lanreotide Autogel (LAN) in Patients (Pts) with Enteropancreatic NETs: Results from CLARINET, a Randomized, Double-Blind, Placebo (Pbo)-Controlled Study

#970

Introduction: Prospective data on antiproliferative effects of somatostatin analogs are lacking in grade 2 and non-midgut tumors.

Aim(s): CLARINET prospectively evaluated the antiproliferative activity of LAN in both intestinal and pancreatic NET (grade 1/2).

Materials and methods: CLARINET was a randomized, double-blind, Pbo-controlled study. Pts who had well/moderately differentiated, with Ki-67<10%, non-functioning enteropancreatic NETs, and no SSA or other medical therapy within last 6 mo, received LAN 120mg (n=101) or Pbo (n=103) every 4 wks for 96 wks or until PD/ death. Primary endpoint PFS and tumor response were evaluated based on centrally assessed CT scans.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Caplin M, Ruszniewski P, Pavel M, Cwikla J, Phan A,

Keywords: tumor response,